Search research articles
Contact Us
Filters
Showing results (101-110 of 109) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 109 results.
The Journal of Urology
|
April 28, 2025
Pelvic Lymph Node Dissection in Prostate Cancer: Is It Really Necessary? A Multicentric Longitudinal Study Assessing Oncological Outcomes in Patients With Prostate Cancer Patients Undergoing Pelvic Lymph Node Dissection vs Radical Prostatectomy Only
Marc A Furrer, Niranjan J Sathianathen, Clancy J Mulholland, et al.
BJU International
|
September 12, 2024
Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics
Matthew J Roberts, Nathan Papa, Hans Veerman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 5, 2023
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database
Louise Emmett, Nathan Papa, William Counter, et al.
The Journal of Urology
|
May 17, 2024
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer
Louise Emmett, Nathan Papa, Thomas A Hope, et al.
European Urology
|
September 1, 2021
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study
Louise Emmett, James Buteau, Nathan Papa, et al.
European Urology Oncology
|
December 7, 2023
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer
James P Buteau, Daniel Moon, Michael T Fahey, et al.
European Urology
|
April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)
Louise Emmett, Nathan Papa, Oliver Sartor, et al.
Radiology
|
April 28, 2026
<sup>177</sup>Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer
Narjess Ayati, Nathan Papa, Megan Crumbaker, et al.
The Lancet. Oncology
|
June 10, 2026
Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
James P Buteau, Daniel Moon, Michael T Fahey, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 109) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 109 results.
The Journal of Urology
|
April 28, 2025
Pelvic Lymph Node Dissection in Prostate Cancer: Is It Really Necessary? A Multicentric Longitudinal Study Assessing Oncological Outcomes in Patients With Prostate Cancer Patients Undergoing Pelvic Lymph Node Dissection vs Radical Prostatectomy Only
Marc A Furrer, Niranjan J Sathianathen, Clancy J Mulholland, et al.
BJU International
|
September 12, 2024
Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics
Matthew J Roberts, Nathan Papa, Hans Veerman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 5, 2023
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database
Louise Emmett, Nathan Papa, William Counter, et al.
The Journal of Urology
|
May 17, 2024
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer
Louise Emmett, Nathan Papa, Thomas A Hope, et al.
European Urology
|
September 1, 2021
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study
Louise Emmett, James Buteau, Nathan Papa, et al.
European Urology Oncology
|
December 7, 2023
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer
James P Buteau, Daniel Moon, Michael T Fahey, et al.
European Urology
|
April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)
Louise Emmett, Nathan Papa, Oliver Sartor, et al.
Radiology
|
April 28, 2026
<sup>177</sup>Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer
Narjess Ayati, Nathan Papa, Megan Crumbaker, et al.
The Lancet. Oncology
|
June 10, 2026
Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
James P Buteau, Daniel Moon, Michael T Fahey, et al.
Page
of 11